IDEXX Laboratories Debt/Equity Ratio 2010-2025 | IDXX

IDEXX Laboratories debt/equity ratio for the quarter ending March 31, 2025 was 0.31.

  • IDEXX Laboratories average debt/equity ratio for 2024 was 0.33, a 44.07% decline from 2023.
  • IDEXX Laboratories average debt/equity ratio for 2023 was 0.59, a 58.16% decline from 2022.
  • IDEXX Laboratories average debt/equity ratio for 2022 was 1.41, a 30.56% decline from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

IDEXX Laboratories Debt/Equity Ratio 2010-2025 | IDXX

  • IDEXX Laboratories average debt/equity ratio for 2024 was 0.33, a 44.07% decline from 2023.
  • IDEXX Laboratories average debt/equity ratio for 2023 was 0.59, a 58.16% decline from 2022.
  • IDEXX Laboratories average debt/equity ratio for 2022 was 1.41, a 30.56% decline from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$171.9B
Thermo Fisher Scientific (TMO)$161.4B
Alcon (ALC)$45.6B
Edwards Lifesciences (EW)$42B
DexCom (DXCM)$26.9B
IQVIA Holdings (IQV)$25.4B
STERIS (STE)$21.8B
Mettler-Toledo (MTD)$20.9B
Waters (WAT)$19.1B
SONOVA HOLDING (SONVY)$17.3B
Fresenius Medical Care AG KGaA (FMS)$13.9B
Hologic (HOLX)$12.9B
Sysmex ADR (SSMXY)$11.8B
Penumbra (PEN)$10.7B
Globus Medical (GMED)$9.8B
Masimo (MASI)$8.2B
Teleflex (TFX)$6B
Glaukos (GKOS)$5.2B
Integer Holdings (ITGR)$4.1B
TransMedics (TMDX)$3B
PROCEPT BioRobotics (PRCT)$2.9B
Veracyte (VCYT)$2.4B
Nihon Kohden (NHNKY)$2.1B
LivaNova (LIVN)$1.9B
Elekta AB (EKTAY)$1.9B
Alphatec Holdings (ATEC)$1.5B
Integra LifeSciences Holdings (IART)$1.2B
Pulse Biosciences (PLSE)$1.2B
Tandem Diabetes Care (TNDM)$1.1B
Paragon 28 (FNA)$1.1B